« Final Report Approved for Large U.S. Population Cohort Project | Home | Results of Clinical Trial in Blood-Based Cancer Detection »
Illumina Introduces High Throughput DNA Methylation Profiling
By Trevor | January 10, 2007
Illumina Inc. (NASDAQ:ILMN) has announced that it has introduced a high-throughput DNA methylation profiling technology capable of surveying up to 1,536 methylation sites across 96 samples simultaneously. From Business Wire:
- By pairing Illumina’s proven BeadArray platform with the GoldenGate(R) assay approach, researchers have the ability to perform genome-wide methylation profiling across multiple areas such as cancer and human embryonic stem cell research. The GoldenGate Methylation Cancer Panel I, the first standard panel, covers 1,505 methylation sites over 800 cancer genes. Custom-content methylation panels will soon be available to meet individual research needs.
Recently, the NCI and the National Human Genome Research Institute (NHGRI) announced two more components of The Cancer Genome Atlas (TCGA) Pilot Project, a three-year, $100 million collaboration established to test the feasibility of using large-scale genome analysis technologies to identify important genetic changes involved in cancer. As part of this project, the Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins University and the Norris Comprehensive Cancer Center of the University of Southern California were awarded funds to establish Cancer Genome Characterization Centers (CGCC). At these centers, researchers will utilize Illumina’s GoldenGate methylation technology to detect changes in methylation profiles associated with transcribed genes in cancer samples.
Related Posts:
Topics: cancer, methylation, news links |
Comments are closed.
